Literature DB >> 17531334

EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: differential response of cancer stem cells and nontumourigenic cells?

Mechthild Krause1, Jenny Prager, Xuanjing Zhou, Ala Yaromina, Annegret Dörfler, Wolfgang Eicheler, Michael Baumann.   

Abstract

BACKGROUND AND
PURPOSE: Waiting times before radiotherapy may reduce tumour control probability due to proliferation of tumour cells. The aim of the experiment was to test whether the growth inhibiting effect of epidermal growth factor receptor (EGFR)-inhibitors after surgery or tumour transplantation results in a lower tumour mass at time of irradiation and can thereby improve local tumour control.
MATERIALS AND METHODS: The EGFR-tyrosine kinase inhibitor BIBX1382BS was applied over 14days starting from microscopically non-in-sano-resection of FaDu tumours or from tumour transplantation, followed by irradiation (5f/5d). Endpoint was local tumour control. In addition, vital tumour areas, pimonidazole hypoxic fraction, BrdU labelling index, and colony forming ability in vitro were tested in control tumours and after BIBX1382BS treatment (starting from transplantation).
RESULTS: The tumour volume at start of irradiation was significantly lower in the BIBX1382BS treated tumours as compared to the control groups by factors of 11 (post-surgery setting) and 2.7 (transplantation setting). However, the reduced volume did not translate into improved local control after irradiation. The TCD(50) values after surgery were 25.4Gy [95% CI 18; 33Gy] in the control group and 30.5Gy [24; 37] in the BIBX1382BS group (p=0.25). Treatment after transplantation resulted in TCD(50) values of 41.1Gy [35; 47] in the control group and 41.1Gy [33; 49] in the BIBX1382BS group (p=1). While the proportion of S-phase cells decreased after BIBX1382BS treatment, no differences were observed between the pimonidazole hypoxic fractions and in vitro colony forming ability.
CONCLUSIONS: EGFR-TK inhibition with BIBX1382BS over 14days between macroscopically complete tumour resection or tumour transplantation and start of radiotherapy significantly reduced tumour volume but did not improve local tumour control. One possible explanation is that the EGFR-TK inhibitor has a higher activity in nontumourigenic cancer cells compared to cancer stem cells. This hypothesis, along with the observation that tumours of similar size were significantly more radiosensitive after surgery than without surgery, warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531334     DOI: 10.1016/j.radonc.2007.04.014

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

Review 1.  Establishing the Impact of Vascular Damage on Tumor Response to High-Dose Radiation Therapy.

Authors:  Katherine D Castle; David G Kirsch
Journal:  Cancer Res       Date:  2019-08-19       Impact factor: 12.701

2.  RNA interference for epidermal growth factor receptor enhances the radiosensitivity of esophageal squamous cell carcinoma cell line Eca109.

Authors:  Heping Zhang; Jiancheng Li; Wenfang Cheng; D I Liu; Cheng Chen; Xiaoying Wang; Xujing Lu; Xifa Zhou
Journal:  Oncol Lett       Date:  2015-07-03       Impact factor: 2.967

3.  Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells.

Authors:  E Dickreuter; I Eke; M Krause; K Borgmann; M A van Vugt; N Cordes
Journal:  Oncogene       Date:  2015-06-15       Impact factor: 9.867

4.  Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy.

Authors:  Everett J Moding; Katherine D Castle; Bradford A Perez; Patrick Oh; Hooney D Min; Hannah Norris; Yan Ma; Diana M Cardona; Chang-Lung Lee; David G Kirsch
Journal:  Sci Transl Med       Date:  2015-03-11       Impact factor: 17.956

5.  Atm deletion with dual recombinase technology preferentially radiosensitizes tumor endothelium.

Authors:  Everett J Moding; Chang-Lung Lee; Katherine D Castle; Patrick Oh; Lan Mao; Shan Zha; Hooney D Min; Yan Ma; Shiva Das; David G Kirsch
Journal:  J Clin Invest       Date:  2014-07-18       Impact factor: 14.808

6.  Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions.

Authors:  Patrizia Marini; Dorothea Junginger; Stefan Stickl; Wilfried Budach; Maximilian Niyazi; Claus Belka
Journal:  Radiat Oncol       Date:  2009-10-27       Impact factor: 3.481

7.  Efficacy of a triple treatment with irradiation, agonistic TRAIL receptor antibodies and EGFR blockade.

Authors:  Maximilian Niyazi; Patrizia Marini; Peter T Daniel; Robin Humphreys; Verena Jendrossek; Claus Belka
Journal:  Strahlenther Onkol       Date:  2009-02-18       Impact factor: 3.621

8.  Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts.

Authors:  Kristin Gurtner; Nadja Ebert; Dorothee Pfitzmann; Wolfgang Eicheler; Daniel Zips; Michael Baumann; Mechthild Krause
Journal:  Radiat Oncol       Date:  2014-12-02       Impact factor: 3.481

9.  Screening and Validation of Molecular Targeted Radiosensitizers.

Authors:  Henning Willers; Xiao Pan; Nathalie Borgeaud; Irina Korovina; Lydia Koi; Regina Egan; Patricia Greninger; Aliza Rosenkranz; Jong Kung; Andrew S Liss; Leslie A Parsels; Meredith A Morgan; Theodore S Lawrence; Steven H Lin; Theodore S Hong; Beow Y Yeap; Lori J Wirth; Aaron N Hata; Christopher J Ott; Cyril H Benes; Michael Baumann; Mechthild Krause
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-07-31       Impact factor: 7.038

Review 10.  Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations.

Authors:  Helen B Stone; Eric J Bernhard; C Norman Coleman; James Deye; Jacek Capala; James B Mitchell; J Martin Brown
Journal:  Transl Oncol       Date:  2016-02       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.